Comparative Pharmacology
Head-to-head clinical analysis: INFLAMASE MILD versus INVELTYS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INFLAMASE MILD versus INVELTYS.
INFLAMASE MILD vs INVELTYS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inflammase Mild is a combination product containing hydrocortisone, a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, thereby inhibiting the release of arachidonic acid and reducing prostaglandin and leukotriene synthesis. It also contains benzalkonium chloride, a quaternary ammonium compound with antiseptic properties.
Corticosteroid; modulates inflammatory response by binding to glucocorticoid receptors, altering gene expression and suppressing pro-inflammatory cytokines.
N/A
Instill 1 drop into the affected eye(s) four times daily for 14 days, then taper as clinically indicated.
None Documented
None Documented
1.5-2.5 hours; short half-life allows frequent dosing for mild inflammation.
Approximately 1.5 hours (range 1-2 hours) for the ophthalmic suspension; terminal half-life in systemic circulation is about 3 hours after topical ocular administration.
Renal excretion of unchanged drug (approximately 60%) and glucuronide conjugate (20%); biliary/fecal (15%).
Primarily hepatic metabolism with minimal renal excretion (<5% unchanged in urine). Fecal elimination accounts for approximately 20% of the dose.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid